We are live on ! Find out more
SAGE

Sage Therapeutics
SAGE

Delisted

SAGE was delisted on the 30th of July, 2025.

Back to rankings

224 hedge funds and large institutions have $2.54B invested in Sage Therapeutics in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 72 increasing their positions, 76 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 18

30% more call options, than puts

Call options by funds: $21.6M | Put options by funds: $16.6M

14% more capital invested

Capital invested by funds: $2.22B → $2.54B (+$321M)

6% more funds holding

Funds holding: 212 → 224 (+12)

1.99% more ownership

Funds ownership: 88.53% → 90.53% (+2%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5% less repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 76

Holders
224
Holders Change
+12
Holders Change %
+5.66%
% of All Funds
3.52%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
31
Increased
72
Reduced
76
Closed
18
Calls
$21.6M
Puts
$16.6M
Net Calls
+$4.98M
Net Calls Change
-$3.09M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$84.9M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$32.3M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$31.7M
4
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$29.5M
5
JP Morgan Chase
JP Morgan Chase
New York
+$15.8M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$41.2M
2
Marshall Wace
Marshall Wace
United Kingdom
-$30.5M
3
BlackRock
BlackRock
New York
-$25.2M
4
State Street
State Street
Massachusetts
-$21.7M
5
Goldman Sachs
Goldman Sachs
New York
-$21.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$18.4M +$286K +5,751 +1%
FC
27
Finepoint Capital
Massachusetts
$16.8M -$1.55M -31,100 -8%
Morgan Stanley
28
Morgan Stanley
New York
$16.5M -$1.03M -20,741 -6%
N
29
Nuveen
North Carolina
$14.7M +$8.64M +173,664 +124%
Franklin Resources
30
Franklin Resources
California
$14.2M -$2.44K -49 -0%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$11.1M -$676K -13,580 -5%
CS
32
Candriam SCA
Luxembourg
$10.7M +$6.82M +137,000 +152%
Citadel Advisors
33
Citadel Advisors
Florida
$10.5M +$8.37M +168,302 +303%
American Century Companies
34
American Century Companies
Missouri
$10.5M +$708K +14,231 +7%
AAP
35
Aristotle Atlantic Partners
Florida
$9.29M +$2.05M +41,107 +26%
PA
36
Pinnacle Associates
New York
$8.56M -$249K -4,997 -3%
DCM
37
DAFNA Capital Management
California
$8.48M – – –
Schroder Investment Management Group
38
Schroder Investment Management Group
United Kingdom
$7.07M +$4.79M +96,378 +179%
Barclays
39
Barclays
United Kingdom
$6.77M -$154K -3,103 -2%
Verition Fund Management
40
Verition Fund Management
Connecticut
$6.54M +$99.9K +2,008 +1%
Rafferty Asset Management
41
Rafferty Asset Management
New York
$6.52M -$1.35M -27,084 -16%
Bank of America
42
Bank of America
North Carolina
$6.39M -$7.37M -148,057 -52%
SFM
43
Sphera Funds Management
Israel
$6.02M -$1.34M -27,000 -17%
Swiss National Bank
44
Swiss National Bank
Switzerland
$5.5M +$74.6K +1,500 +1%
Invesco
45
Invesco
Georgia
$5.17M +$2.54M +51,104 +87%
Allianz Asset Management
46
Allianz Asset Management
Germany
$5.08M -$406K -8,163 -7%
Allspring Global Investments
47
Allspring Global Investments
North Carolina
$4.83M +$408K +8,200 +9%
Jane Street
48
Jane Street
New York
$4.72M +$3.05M +61,240 +157%
TC
49
TwinBeech Capital
New York
$4.49M +$4.1M +82,316 +628%
Baillie Gifford & Co
50
Baillie Gifford & Co
United Kingdom
$4.41M -$66K -1,326 -1%
1
2
3 4 5

SAGE Hedge Fund Activity: Q2 2023 in Review

224 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q2 2023, worth a combined $2.54B — up 14% from $2.22B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new SAGE positions and 18 closed out — a net gain of 13 holders — while 72 added to existing stakes and 76 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $84.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $41.2M.

  • 224 institutional investors held Sage Therapeutics (SAGE) as of Q2 2023, up from 212 in Q1 2023.
  • Funds reported $2.54B of Sage Therapeutics stock for Q2 2023, up 14% quarter-over-quarter.
  • 31 funds opened new Sage Therapeutics positions in Q2 2023 and 18 closed out, a net change of +13 holders.
  • The largest Sage Therapeutics buyer in Q2 2023 was Fidelity Investments, an estimated $84.9M added.
  • The largest Sage Therapeutics seller in Q2 2023 was T. Rowe Price Associates, an estimated $41.2M sold.

Based on aggregated 13F filings for Q2 2023.